Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ISRCTN10648713) titled 'Sleep Blinding Psilocybin, a feasibility study: Examining if participants can tell if they received psilocybin or a placebo when medication is given to act in sleep' on April 15.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Blinded (masking used)
Control: Placebo
Assignment: Crossover
Purpose: Treatment
Primary Sponsor: King's College London
Condition:
Depression
Mental and Behavioural Disorders
Intervention:
The study will run through stages progressively, with one stage running until finished and then moving to the next stage
Phase 1
Stage 1
Overview
The ...